Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab in Recurrent or Progressive Malignant Brain Tumors
NCT05169944Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in brain tumor, sponsored by University of California, San Francisco. Primary endpoints: Recommended Phase 2 Dose and Proportion of participants with treatment-emergent adverse events up to 12 months. Started Apr 2022; status: completed.
02
Drugs
magrolimab
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT05169944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169944.